Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?

被引：16

作者：

Di Rocco, Alice ^{[1
]}

De Angelis, Federico ^{[1
]}

Ansuinelli, Michela ^{[1
]}

Foa, Robin ^{[1
]}

Martelli, Maurizio ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Via Benevento 6, I-00161 Rome, Italy

来源：

EXPERT REVIEW OF HEMATOLOGY | 2017年 / 10卷 / 09期

关键词：

Diffuse large B cell lymphoma (DLBCL); cell of origin (COO); germinal centre-B cell like (GCB); activated B cell (ABC); rituximab; CHOP regimen; immunohistochemistry (IHC); gene expression profiling (GEP); RITUXIMAB PLUS CYCLOPHOSPHAMIDE; DOUBLE-HIT LYMPHOMA; NF-KAPPA-B; R-CHOP; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; PROTEIN EXPRESSION; ELDERLY-PATIENTS; BCL6; REARRANGEMENTS; MUTATIONS PREDICT;

D O I：

10.1080/17474086.2017.1356714

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder. Novel additional predictors of outcomes and new therapeutic strategies are being introduced to improve outcomes.Areas covered: This review aims to analyse the recent molecular discoveries in DLBCL, the rationale of novel molecular driven treatments and their impact on DLBCL prognosis, especially in ABC-DLBCL and High Grade B Cell Lymphoma. Pre-clinical and clinical evidences are reviewed to critically evaluate the novel DLBCL management strategies.Expert commentary: New insights in DLBCL molecular characteristics should guide the therapeutic approach; the results of the current studies which are investigating safety and efficacy of novel X-RCHOP' will probably lead, in future, to a cell of origin (COO) based upfront therapy. Moreover, it is necessary to identify early patients with DLBCL who carried MYC, BCL2 and/or BCL6 rearrangements double hit lymphomas (DHL) because they should not receive standard R-CHOP but high intensity treatment as reported in many retrospective studies. New prospective trials are needed to investigate the more appropriate treatment of DHL.

引用

页码：761 / 774

页数：14

共 107 条

[1] Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab [J].

Akyurek, Nalan ;

Uner, Aysegul ;

Benekli, Mustafa ;

Barista, Ibrahim .

CANCER, 2012, 118 (17) :4173-4183

[2] De novo CD5+diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort [J].

Alinari, Lapo ;

Gru, Alejandro ;

Quinion, Carl ;

Huang, Ying ;

Lozanski, Arletta ;

Lozanski, Gerard ;

Poston, Jacqueline ;

Venkataraman, Girish ;

Oak, Eunhye ;

Kreisel, Friederike ;

Park, Steven I. ;

Matthews, Stephanie ;

Abramson, Jeremy S. ;

Lim, Hana Iris ;

Martin, Peter ;

Cohen, Jonathon B. ;

Evens, Andrew ;

Al-Mansour, Zeina ;

Singavi, Arun ;

Fenske, Timothy S. ;

Blum, Kristie A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (04) :395-399

[3] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[4]

[Anonymous], 2015, BLOOD

[5] Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma [J].

Aukema, Sietse M. ;

Kreuz, Markus ;

Kohler, Christian W. ;

Rosolowski, Maciej ;

Hasenclever, Dirk ;

Hummel, Michael ;

Kueppers, Ralf ;

Lenze, Dido ;

Ott, German ;

Pott, Christiane ;

Richter, Julia ;

Rosenwald, Andreas ;

Szczepanowski, Monika ;

Schwaenen, Carsten ;

Stein, Harald ;

Trautmann, Heiko ;

Wessendorf, Swen ;

Truemper, Lorenz ;

Loeffler, Markus ;

Spang, Rainer ;

Kluin, Philip M. ;

Klapper, Wolfram ;

Siebert, Reiner .

HAEMATOLOGICA, 2014, 99 (04) :726-735

[6] Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma [J].

Barrans, SL ;

O'Connor, SJM ;

Evans, PAS ;

Davies, FE ;

Owen, RG ;

Haynes, AP ;

Morgan, GJ ;

Jack, AS .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) :322-332

[7] Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction [J].

Bea, S ;

Zettl, A ;

Wright, G ;

Salaverria, I ;

Jehn, P ;

Moreno, V ;

Burek, C ;

Ott, G ;

Puig, X ;

Yang, LM ;

Lopez-Guillermo, A ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Gascoyne, RD ;

Connors, JM ;

Grogan, TM ;

Braziel, R ;

Fisher, RI ;

Smeland, EB ;

Kvaloy, S ;

Holte, H ;

Delabie, J ;

Simon, R ;

Powell, J ;

Wilson, WH ;

Jaffe, ES ;

Montserrat, E ;

Muller-Hermelink, HK ;

Staudt, LM ;

Campo, E ;

Rosenwald, A .

BLOOD, 2005, 106 (09) :3183-3190

[8] Origins and functions of B-1 cells with notes on the role of CD5 [J].

Berland, R ;

Wortis, HH .

ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :253-300

[9] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs [J].

Boi, Michela ;

Gaudio, Eugenio ;

Bonetti, Paola ;

Kwee, Ivo ;

Bernasconi, Elena ;

Tarantelli, Chiara ;

Rinaldi, Andrea ;

Testoni, Monica ;

Cascione, Luciano ;

Ponzoni, Maurilio ;

Mensah, Afua Adjeiwaa ;

Stathis, Anastasios ;

Stussi, Georg ;

Riveiro, Maria Eugenia ;

Herait, Patrice ;

Inghirami, Giorgio ;

Cvitkovic, Esteban ;

Zucca, Emanuele ;

Bertoni, Francesco .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1628-1638

[10] The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target [J].

Cardenas, Mariano G. ;

Oswald, Erin ;

Yu, Wenbo ;

Xue, Fengtian ;

MacKerell, Alexander D., Jr. ;

Melnick, Ari M. .

CLINICAL CANCER RESEARCH, 2017, 23 (04) :885-893

← 1 2 3 4 5 6 7 8 9 10 →